Anti-anxiety and sedative profile evaluation of imidazo[1,2-a]pyridine derivatives

Drug Development Research

Volumn 71, Issue 6, 2010, Pages 371-381

  López Martínez, Margarita ^a   Salgado Zamora, Héctor ^a   San Juan, Eduardo Ramírez ^a   Zamudio, Sergio ^a   Picazo, Ofir ^a   Campos, Maria Elena ^a   Naranjo Rodriguez, Elia B ^b  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Anxiety; Behavioral tests; Imidazo 1,2 a pyridines; Sedation

Indexed keywords

2 (3' TRIFLUOROMETHYLPHENYL) 3 NITROSO IMIDAZO[1,2 A]PYRIDINE; 2 (3',4' DIMETHOXYPHENYL) 3 NITROSOIMIDAZO[1,2 A]PYRIDINE; 2 (4' CHLOROPHENYL) 3 NITROSO IMIDAZO[1,2 A]PYRIDINE; 2 (4' METHOXYPHENYL) 3 FORMYLIMIDAZO[1,2 A]PYRIDINE THIOSEMICARBAZONE; DIAZEPAM; IMIDAZO[1,2 A]PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; ZOLPIDEM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; BEHAVIORAL STRESS; CONTROLLED STUDY; LATENT PERIOD; LOCOMOTION; MALE; MAZE TEST; MOTOR ACTIVITY; NONHUMAN; ROTAROD TEST; SEDATION; TASK PERFORMANCE; TRANQUILIZING ACTIVITY;

EID: 77957198848     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20382     Document Type: Article

References (30)

1. Benavides J, Peny B, Dubois A, Perrault G, Morel E, Zivkovic B, Scatton B. 1988. In vivo interaction of zolpidem with central benzodiazepine (BZD) binding sites (as labeled by 3HRo 15-1788) in the mouse brain. Preferential affinity of zolpidem for ω1(BZD1) subtype. J Pharmacol Exp Ther 245:1033.
2. Berson A. 2001. Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation. J Pharmacol Exp Ther 299:793-800.
3. Bonetti, E. 1982. Benzodiazepine antagonist Ro 15-1788: neurological and behavioral effects. Psychopharmacology 78:8-18. (Pubitemid 12036012)
4. Chaouni-Benabdallah A, Galtier C, Allouchi H, Kherbeche A, Debouzy JC, Teulade JC, Chavignon O, Witvrouw M, Pannecouque C, Balzarini J, de Clercq E, Enguehard C, Gueiffier A. 2001. Synthesis of 3-nitrosoimidazo[1,2-a]pyridine derivatives as potential antiretroviral agents. Arch Pharm 334:224-228. (Pubitemid 32751531)
5. Davidson JR. 2002. Pharmacotherapy of generalized anxiety disorder. J Clin Psych 63(Suppl 14):9-16.
6. Depoorte H, Zivkovic B, Lloyd KG, Sanger DJ, Perrault G, Bartholini G. 1986. Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behabioral effects. J Pharmacol Exp Ther 237:649-658. (Pubitemid 16092830)
7. Dunham NM, Miya TS. 1956. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc 46:208-209.
8. Feldman RS, Meyer JS, Quenzer LF. 1997. Sedative-hypnotic and anxiolytic drugs. In: Principles of neuropsychopharmacology. Sinauer, MA: EUA. p 673-729.
9. Frankowska M, Filip M, Przegalinski E. 2007. Effects of GABAB receptor ligands in animal test of depression and anxiety. Pharmacol Report 59:645-655. (Pubitemid 351586555)
10. Fuentes O, Paudler WW. 1975. Some formylation reactions of imidazo [1,5-a] pyridine and pyrrocoline. J Heterocyclic Chem 12:379-383.
11. Kent JM, Mathew SJ, Gorman JM. 2002. Molecular targets in the Treatment of anxiety. Soc Biol Psych 52:1008-1030.
12. Langer SZ, Depoortere H, Sanger DJ, George P, Zivkovic B, Arbilla S, Lloyd KG, Bartholini G. 1985. Biochemical and pharmacological profile of SL 80.0570-23N, a new short acting hyonotic. J Neurochem 44:179.
13. Lippa AS, Klepner CA, Yunger L, Sano MC, Smith WV, Beer B. 1978. Relationship between benzodiazepine receptors and experimental anxiety in rats. Pharmacol Biochem Behav 9:853-856. (Pubitemid 9131603)
14. Lombardino JG. 1965. Preparation and new reactions of imidazo [1m2-apytidines. J Otg Chem 30:2403-2407.
15. McKernan RM, Rosal TW, Reynols DS, Sur C, Waffor KA, Atack JR, Farrar S, Myers J, Cook G, Ferris P, Garrent L, Bristo L, Marshall G, Macaulay A, Brown N, Howell O. 2000. Sedative but no anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha 1 subtype. Nat Neurosci 3:587-592.
16. Pellow S, File SE. 1986. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in rat. Pharmacol Biochem Behavior 24:525-529. (Pubitemid 16145187)
17. Pellow S, Chopin P, File SE, Briley Mike. 1985. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in he rat. J Neurosci Methods 14:149-167. (Pubitemid 16239568)
18. Picazo O, Fernández-Guasti A. 1995. Anti-anxiety effects of progesterone and some of its reduced metabolites: an evaluation using the burying behavior test. Brain Res 680:135-141.
19. Pinel JP, Treit D. 1978. Buying as a defensive response in rats. J Comp Physiol Psychol 92:708-712.
20. Ressler KJ, Mayber HS. 2007. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci 10:1116-1124.
21. Rudolph U, Crestani F, Benke D, Brünig I, Benson JA, Fritschy JM, Martin JR, Bluethmann H, Möhler H. 2000. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 404:629.
22. Salgado-Zamora H, Velazquez M, Mejia D, Campos-Aldrete ME, Jimenez R, Cervantes H. 2008. Influence of the 2-aryl group on the ipso electrophilic substitution process of 2-aryl imidazo[1,2-apyridines. Heterocyclic Commun 14:27-32.
23. Soderpalm B, Eriksson E, Jorgen AE. 1989. Anticonflict and rotarod impairing effects of alprazolam and diazepam in rat after acute and subchronic administration. Prog Neuro-Psychopharmacol Biol Psychiat 13:269-283. (Pubitemid 19120555)
24. Srivastava P, Pandevy VCh, Misra A, Gupta P, Raj K, Bhaduri P. 1998. Potential inhibitors of plasmodial heme oxygenase; an innovative approach for combating chloroquine resistant malaria. Bioorg Med Chem 6:181-187. (Pubitemid 28260933)
25. Treit D. 1985. Animal models for the study of anti-anxiety agents: a review. Neurosci Biobehav Rev 9:203-222. (Pubitemid 15079228)
26. Treit D, Terlecki LJ, Pinel JPJ. 1980. Conditioned defensive burying in rodents: Organismic variables. Bull Psychonomic Soc 16:445-451.
27. Treit D, Pinel JP, Fibiger HC. 1981. Conditioned defensive burying: a new paradigm for the study of anxiolytic agents. Pharmacol Biochem Behav 15:619-626. (Pubitemid 11015566)
28. West DX, Gebremedhin H, Butcher RJ, Jasinski JP, Liberta AE. 1993. Structures of nickel(II) and copper(II) complexes of 2-acetylpyridine azacyclothiosemicarbazones. Polyhedron 12:2489-2497.
29. Wittchen HU, Hoyer J. 2001. Generalized anxiety disorder: nature and course. J Clin Psych 62:15-49.
30. Yu L, Lopez A, Anaflous A, El Bali B, Hamal A, Ericson E, Lawrence E, Heisler LE, McQuibban A, Giaever G, Nislow C, Boone Ch GW, Brown GW, Mohammed BM. 2008. Chemical-genetic profiling of imidazo[1,2-a]pyridines and -pyrimidines reveals target pathways conserved between yeast and human cells. PLoS Genet 4:e1000284.